Introduction
The US heart failure (HF) population currently numbers 6 million and is projected to increase to 8.5 million by 2030 . 1 Over half of these patients have HF with preserved ejection fraction (HFpEF), and the incidence of this disease is increasing rapidly. 2, 3 HFpEF has been associated with accelerated cognitive decline; however, the exact mechanism of this decline remains unclear. 4 Although atrial fibrillation (AF) is a common co-morbidity in this patient group, 5, 6 the proportion of patients with HFpEF and undiagnosed paroxysmal AF is unknown. Evidence is emerging that AF is associated with cognitive impairment or dementia even in individuals without a history of clinical stroke. 7 In addition, it has been recently demonstrated that by the time AF is diagnosed, subclinical cerebral infarctions (SCIs) can be detected by magnetic resonance imaging (MRI) along with measureable cognitive deficits. 8 The presence of these infarctions in brain MRI in patients with HFpEF and no prior diagnosis of AF may suggest that AF is being missed.
In this study, we analysed whether a clinical diagnosis of HFpEF was associated with the presence of SCIs by brain MRI in individuals with no history of AF. We also assessed whether these SCIs were associated with cognitive impairment. Our overarching hypothesis was that undetected AF may be common in the HFpEF population and that failure to detect this may lead to subclinical brain infarcts and cognitive decline.
Methods

Study population
The Atherosclerosis Risk in Communities (ARIC) Study involves a predominantly biracial, population-based cohort drawn from four communities in North Carolina, Mississippi, Minnesota and Maryland. The cohort enrolled 15 792 men and women between the ages of 45 and 64 years during the years of 1987-89 (Visit 1). 9 Four additional visits have subsequently taken place, the last of which was Visit 5 (2011-13) . In compliance with the Declaration of Helsinki, the ARIC Study protocol was approved by the institutional review board of each participating centre and informed consent was obtained from each study participant.
Inclusion criteria
As part of Visit 5, participants were invited to undergo a transthoracic echocardiogram and extensive cognitive assessment, as part of the ARIC Neurocognitive Study (ARIC-NCS). A subset of Visit 5 participants were selected for brain MRI. This subset included subjects in whom previous brain MRI had been performed during 2004-06, subjects with low cognitive test scores, and an age-stratified random sample of the remaining individuals. 10 For the present analysis, we included cohort participants for whom the following data were obtained at Visit 5: echocardiogram; brain MRI, and cognitive tests. Individuals were also required to have complete data regarding incident HF and previous or current AF up to and including at Visit 5.
Exclusion criteria
Exclusion criteria included the following: (i) a diagnosis of Alzheimer's disease prior to Visit 5 as these subjects have a different mechanism for cognitive deficit (n = 212); (ii) prevalent stroke defined as any adjudicated stroke prior to Visit 5 (n = 71); 11 (iii) prior open heart surgery because a different mechanism for SCIs via cardiopulmonary bypass applies in these subjects (n = 22); (iv) end-stage renal disease (defined as an estimated glomerular filtration rate of <15 mL/min/m 2 at Visit 5) as HFpEF cannot be diagnosed in this setting (n = 7); (v) a history of a permanent pacemaker as these patients will not have undiagnosed AF (n = 1); (vi) belonging to a racial/ethnic group other than White or Black or non-Whites in the Minneapolis and Washington County field centres (n = 13); (vii) absence of covariate data (n = 3); and (viii) HF with reduced ejection fraction (HFrEF) (n = 14).
Variable definitions Heart failure with preserved ejection fraction
The definition of HFpEF was based on a prior history of hospitalization for HF or a self-reported physician diagnosis of HF or HF medication
use at Visit 5 and a left ventricular ejection fraction (LVEF) of ≥50% by Visit 5 echocardiogram. 12, 13 Heart failure medication use was obtained by asking cohort subjects whether or not they had taken HF medications in the 2 weeks prior to the study visit.
Atrial fibrillation
The presence of AF at Visit 5 was defined by either a hospital discharge record during follow-up showing an ICD-9-CM code for AF (427.31 or 427.32) or by AF as detected by an ECG performed during any ARIC Study visit including Visit 5.
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Subclinical infarcts
Brain MRIs were performed at each site on 3 Tesla Siemens (various models) scanners using a common set of sequences that included 3-dimensional volumetric magnetization prepared gradient echo and fluid-attenuated inversion recovery sequences. Brain infarcts were identified, counted and measured by a trained imaging technician and confirmed by radiologists as previously described. 15 SCIs were defined as focal, non-mass lesions of ≥3 mm that were bright on T2 and proton density and dark on T1 images.
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Neurocognitive function
All ARIC Study cognitive assessments were administered by trained examiners in a standard order. Detailed descriptions of each test have been published previously. 16 For each individual test, standardized Z-scores were calculated. A list of the cognitive tests used in this analysis can be found in the Supplementary material online (Table S1 ).
Covariates
Prespecified potential confounders of the relationship between HFpEF and SCI were measured at Visit 5 and were included in the models. These ARIC variables have established definitions, which were also used for this analysis. 17 Briefly, we included the following: age; sex; race; education, and smoking status. Hypertension was defined as systolic blood pressure of ≥140 mmHg, diastolic blood pressure of ≥90 mmHg, or use of blood pressure-lowering medications. Diabetes was defined as a fasting glucose level of ≥126 mg/dL or a non-fasting glucose level of ≥200 mg/dL, a self-reported physician diagnosis of diabetes, or use of diabetes medications. Blood samples were collected following a fast of at least 8 h, and total cholesterol was determined by enzymatic methods. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared. Coronary heart disease (CHD) prior to Visit 1 was defined as physician-diagnosed CHD or the presence of a previous myocardial infarction by ECG. Patients were also classified as having CHD if an adjudicated coronary event occurred after Visit 1. Waist-to-hip ratio from Visit 5, family history of stroke and physical activity from Visit 3 were also incorporated into the adjusted models as these have also been associated with SCI.
18,19 Data on anticoagulant use, defined as warfarin, direct thrombin inhibitor or factor Xa inhibitor use, were obtained by self-reported medication intake during the previous 2 weeks and by reviewing medications brought by the participant to the visit. prevalence independently of AF diagnosis, we divided the sample into four groups consisting of participants with no HFpEF and no AF (no HFpEF/no AF), those with no HFpEF and with AF (no HFpEF/AF), those with HFpEF and no AF (HFpEF/no AF), and those with HFpEF and AF (HFpEF/AF). Numbers of SCIs by brain MRI and baseline characteristics were compared among these four groups using analysis of variance (ANOVA) and 2 analyses as appropriate. Logistic regression was used to assess the odds ratios (ORs) of SCIs in each participant group against the reference group (no HFpEF/no AF), and also to assess the association of SCIs with HFpEF. A series of nested models were fit. Model 1 was adjusted for age, sex and race. Model 2 included Model 1 covariates plus enrolling centre, education (did not complete high school vs. completed high school), hypertension, diabetes, smoking status (current smoker vs. not a current smoker), BMI, total cholesterol, family history of stroke, waist-to-hip ratio and physical activity. Model 3 included Model 2 covariates plus Among the HFpEF/no AF group, logistic regression was used to identify clinical variables that conferred increased odds of SCI. The univariate associations were examined, and then a multivariable model adjusting for variables with a P-value for the association of <0.10 was applied using a backwards stepwise covariate selection approach.
Next, linear regression was used to compare cognitive Z-scores from each test among the four participant groups, using the no HFpEF/no AF group again as the reference group. In this analysis, Model 1 adjusted for age, sex and race. Model 2 included Model 1 plus centre, education, hypertension, diabetes, smoking, BMI, total cholesterol, prevalent CHD, anticoagulant use and prevalent AF. All models comparing cognitive scores were weighted to account for 
Results
Of the initial ARIC cohort, 6538 participants completed Visit 5. Of these, 1870 had complete cognitive scores as well as brain MRI and echocardiogram data; the final cohort after the application of all inclusion and exclusion criteria numbered 1527 subjects. Among the 1527 cohort participants, 201 (13.2%) had HFpEF. Eighty-seven subjects (5.7%) had a prior or current diagnosis of AF and 290 subjects (19.0%) demonstrated the presence of SCIs. The mean ± standard deviation (SD) age of the study cohort at Visit 5 was 76.0 ± 5.3 years. Descriptive statistics according to HF and AF status are presented in Table 1 . Individuals in the HFpEF/no AF group were less likely to be on warfarin (4.8%) than those with a diagnosis of AF [32.0% (P < 0.0001) in the no HFpEF/AF group and 67.8% (P < 0.0001) in the HFpEF/AF group]. Those in the HFpEF/no AF group were also more likely to be African American than participants in all other groups (P < 0.0001).
High prevalence of subclinical cerebral infarction in subjects with HFpEF/no AF
Cohort participants with HFpEF but no prior diagnosis of AF had a high prevalence of SCI by brain MRI (49/167, 29.3%), which did not differ statistically from that in the no HFpEF/AF (13/53, 24.5%; P = 0.46) and HFpEF/AF (8/34, 23.5%; P = 0.63) groups, but was higher than that in the no HFpEF/no AF reference group (220/1273, 17.3%; P < 0.0001). The odds of having SCI were higher in subjects with HFpEF/no AF than in the non-HF cohort even after adjustment for other potential confounders [minimally adjusted OR 1.92 Left atrial enlargement is a risk factor for subclinical cerebral infarction in subjects with HFpEF/no AF Among subjects with HFpEF and no AF diagnosis, only male sex and a larger left atrium were associated with increased odds of having SCI after a backwards selection of variables had been applied ( Table 3) . In the adjusted model, for each SD increase in the left atrial volume index, the odds of SCI were increased by 41% (OR 1.41, 95% CI 1.00-2.00). Male sex was also associated with increased odds of SCI (OR 2.26, 95% CI 1.12-4.58) ( Table 3) . Increased left ventricular mass index was associated with increased odds of SCI in the univariate model, but this increase did not remain significant after adjustment in this small HFpEF/no AF population.
Subclinical cerebral infarction in subjects with HFpEF is associated with lower cognitive performance
The presence of SCI in subjects with HFpEF was associated with lower cognitive scores in several tests compared with the reference (no HF/no SCI) group (Table 4) . In the final multivariable model, subjects with HFpEF but no SCI had cognitive scores similar to those in the no HFpEF/no AF group, suggesting that SCI, and not HFpEF alone, may have been the mechanism behind the cognitive impairment. 
Discussion
This analysis of the ARIC Study cohort demonstrates that individuals with HFpEF but no prior AF diagnosis had a high prevalence of SCI as detected by brain MRI. The odds of having SCI in this group were higher than in the no HFpEF/no AF group even after multivariable adjustment. Risk factors for SCI in the HFpEF/no AF group included LA enlargement, which is strongly associated with AF. 20, 21 Atrial fibrillation is known to be a risk factor for SCI 22, 23 and its detection rises when surveillance increases in high-risk populations. 24, 25 Undiagnosed paroxysmal AF, therefore, may explain the SCI observed in this cohort of HFpEF subjects.
Another 26 -28 Regardless of whether left atrial myopathy or undetected paroxysmal AF are responsible for the higher prevalence of SCI, these data suggest there may be a role for earlier anticoagulation in HFpEF to prevent the occurrence of this mechanism of cognitive decline.
The lower cognitive scores observed in the HFpEF group appear to have been mediated through the SCI rather than the HFpEF alone. The presence of cognitive deficits that may be attributable to these small infarcts also underscores their clinical importance. To put the degree of cognitive deficit observed in subjects with HFpEF and SCI into context, the −0.5 lower Z-score observed on many of the cognitive tests is equivalent to the degree of cognitive decline that would be expected to occur over 10 years of ageing. 29 Cognitive impairment is also known to negatively impact quality of life and can lead to a loss of independence, both of which are of extreme importance to the ageing population. 30 As the epidemic of HFpEF continues to develop, it will be increasingly important to prevent the occurrence of any loss of cognitive function. It is not presently clear why subjects with HFpEF outnumbered those with HFrEF in this cohort. This ratio was also observed in the Cardiovascular Health Study (conducted in people aged 66-103 years), which investigated a population in an age range similar to that of the ARIC Study cohort at Visit 5. In this study, 80% of HF cases had an LVEF of >45%. 31 Other possibilities include the recovery of left ventricular function by the time an echo was performed or survival bias as mortality is higher in HFrEF than in HFpEF.
Although the prevalence of AF among those with HFpEF was similar to levels reported in previously published studies, 32, 33 we did not find a statistical increase in the odds of SCI in those with AF after multivariable adjustment. This may reflect the low number of participants in these subgroups and potentially may be attributable to the higher use of anticoagulants in these groups.
Limitations
Given the relatively healthy population that participated in the ARIC Study Visit 5, the number of patients with a diagnosis of HFpEF or AF was relatively small. Despite this, we found a statistically significant association with SCI even after adjustment, and the prevalence rates of HFpEF in this study were similar to rates in the USA. 34 Subclinical infarcts were defined as focal, non-mass lesions of ≥3 mm that were bright on T2 and proton density and dark on T1 images. Therefore, participants with SCIs of <3 mm may have been misclassified, although lesions of this size are usually considered to be enlarged perivascular spaces. We cannot be certain that patients with a normal ejection fraction by echocardiogram and a clinical diagnosis of HF did not have a history of HFrEF that recovered. That this study was a cross-sectional analysis limits our ability to interpret causality and we do not know definitively that AF was the direct mechanism of SCI.
Conclusions
Subclinical cerebral infarctions were prevalent in cohort subjects with HFpEF and no prior AF diagnosis and are associated with measurable cognitive deficits. Although other sources of emboli may be possible, these data suggest that paroxysmal AF may be underdiagnosed in this population. There may be a role for increased heart rhythm surveillance or earlier anticoagulation in patients with HFpEF to prevent the action of this mechanism of cognitive decline.
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